Clinical trial
Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
NCT03724981 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 18, 2018
- Completion date
- April 12, 2019
- Enrollment
- 312 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.